Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report
Abstract Background NRG1 fusions are rare oncogenic drivers in solid tumors, and the incidence of NRG1 fusions in non-small cell lung cancer (NSCLC) was 0.26%. It is essential to explore potential therapeutic strategies and efficacy predictors for NRG1 fusion-positive cancers. Case presentation We r...
Main Authors: | Xin Nie, Ping Zhang, Zhixin Bie, Chenhui Song, Min Zhang, Di Ma, Di Cui, Gang Cheng, Hui Li, Yan Lei, Xiaoxing Su, Wendy Wu, Lin Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-08-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12957-023-03129-z |
Similar Items
-
Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer
with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review
by: Chunmei CHEN, et al.
Published: (2024-05-01) -
A case of multiple primary lung adenocarcinoma with a CD74‐NRG1 fusion protein and HER2 mutation benefit from combined target therapy
by: Kai Chen, et al.
Published: (2022-11-01) -
Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
by: Lingling Zhao, et al.
Published: (2021-04-01) -
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
by: Teng Li, et al.
Published: (2021-11-01) -
Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements
by: Xiaomei Zhang, et al.
Published: (2024-01-01)